Search research articles
Contact Us
Filters
Showing results (61-70 of 86) with videos related to
Page
of 9
Sort By:
Journal of Medicinal Chemistry
|
September 1, 1987
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines
D J Hlasta, D Luttinger, M H Perrone, et al.
The Journal of Infectious Diseases
|
September 9, 1999
Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients
D N Forthal, G Landucci, R Haubrich, et al.
Life Sciences
|
May 24, 1982
Potent dopamine agonist activity of a novel ergoline, 6-ethyl-9-oxaergoline (EOE)
G E Martin, M Williams, B V Clineschmidt, et al.
Antimicrobial Agents and Chemotherapy
|
November 16, 2001
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
B M Sadler, C Gillotin, Y Lou, et al.
European Journal of Pharmacology
|
March 16, 1984
Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists
G G Yarbrough, J McGuffin-Clineschmidt, D K Singh, et al.
AIDS Research and Human Retroviruses
|
August 10, 2000
Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group
D A Katzenstein, M Hughes, M Albrecht, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 8, 2001
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir
J J Eron, R Haubrich, W Lang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 19, 2001
Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus
S Becker, A Fisher, C Flexner, et al.
European Journal of Pharmacology
|
April 10, 1990
Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain
R A Ferrari, S J Ward, C M Zobre, et al.
The Journal of Infectious Diseases
|
March 14, 1998
Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group
D V Havlir, R Haubrich, J Hwang, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 86) with videos related to
Sort By:
Page
of 9
Journal of Medicinal Chemistry
|
September 1, 1987
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines
D J Hlasta, D Luttinger, M H Perrone, et al.
The Journal of Infectious Diseases
|
September 9, 1999
Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients
D N Forthal, G Landucci, R Haubrich, et al.
Life Sciences
|
May 24, 1982
Potent dopamine agonist activity of a novel ergoline, 6-ethyl-9-oxaergoline (EOE)
G E Martin, M Williams, B V Clineschmidt, et al.
Antimicrobial Agents and Chemotherapy
|
November 16, 2001
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
B M Sadler, C Gillotin, Y Lou, et al.
European Journal of Pharmacology
|
March 16, 1984
Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists
G G Yarbrough, J McGuffin-Clineschmidt, D K Singh, et al.
AIDS Research and Human Retroviruses
|
August 10, 2000
Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group
D A Katzenstein, M Hughes, M Albrecht, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 8, 2001
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir
J J Eron, R Haubrich, W Lang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 19, 2001
Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus
S Becker, A Fisher, C Flexner, et al.
European Journal of Pharmacology
|
April 10, 1990
Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain
R A Ferrari, S J Ward, C M Zobre, et al.
The Journal of Infectious Diseases
|
March 14, 1998
Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group
D V Havlir, R Haubrich, J Hwang, et al.
Page
of 9